Cargando…

Clinical and biochemical study of d-serine metabolism among schizophrenia patients

BACKGROUND: Schizophrenia is a typical N-methyl-d-aspartate receptor (NMDA-R) hypofunction disorder. Decreased d-serine (d-Ser) levels in the periphery occur in schizophrenia and may reflect decreased availability of d-Ser to activate NMDA-R in the brain. OBJECTIVE: The objective of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Tallawy, Hamdy N, Saleem, Tahia H, El-Ebidi, Abdallah MAA, Hassan, Mohammed H, Gabra, Romany H, Farghaly, Wafaa MA, Abo El-Maali, Nagwa, Sherkawy, Hoda S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391825/
https://www.ncbi.nlm.nih.gov/pubmed/28435276
http://dx.doi.org/10.2147/NDT.S126979
_version_ 1783229340867100672
author El-Tallawy, Hamdy N
Saleem, Tahia H
El-Ebidi, Abdallah MAA
Hassan, Mohammed H
Gabra, Romany H
Farghaly, Wafaa MA
Abo El-Maali, Nagwa
Sherkawy, Hoda S
author_facet El-Tallawy, Hamdy N
Saleem, Tahia H
El-Ebidi, Abdallah MAA
Hassan, Mohammed H
Gabra, Romany H
Farghaly, Wafaa MA
Abo El-Maali, Nagwa
Sherkawy, Hoda S
author_sort El-Tallawy, Hamdy N
collection PubMed
description BACKGROUND: Schizophrenia is a typical N-methyl-d-aspartate receptor (NMDA-R) hypofunction disorder. Decreased d-serine (d-Ser) levels in the periphery occur in schizophrenia and may reflect decreased availability of d-Ser to activate NMDA-R in the brain. OBJECTIVE: The objective of this study was to investigate the role of d-Ser metabolism in the pathogenesis of schizophrenia via biochemical assays and correlates, the serum level of d-Ser, d-serine racemase (SR) (responsible for its formation from l-serine [l-Ser]) and d-amino acid oxidase (DAAO) (responsible for its catabolism), among different clinical types of schizophrenia patients. PATIENTS AND METHODS: This cross-sectional case–control study was carried out on 100 patients and 50 controls. They were recruited from the outpatients’ psychiatric unit of the Neuropsychiatric Department of Assiut University Hospital, Upper Egypt. The type of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), while the severity of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Serum d-Ser levels were estimated using high-performance liquid chromatography (HPLC), while serum SR and DAAO were measured using commercially available enzyme-linked immunosorbent assay kits. RESULTS: There were significantly lower mean serum levels of d-Ser and SR and significantly higher mean serum levels of DAAO (P-value <0.01 for each) among schizophrenia patients when compared with the control group. Paranoid schizophrenia had the highest frequency, with a significantly lower serum levels of d-Ser and SR in the residual type and significantly higher serum levels of DAAO in undifferentiated and catatonic types. Combined receiver-operating characteristic curve for serum d-Ser, SR and DAAO indicated that the best serum level cutoff points at which schizophrenia manifestations started to appear were ≤ 61.4 mg/L for d-Ser, ≤ 15.5 pg/mL for SR and >35.6 pg/mL for DAAO. CONCLUSION: The present study confirms that disturbed d-Ser metabolism could be implicated in the pathogenesis of schizophrenia.
format Online
Article
Text
id pubmed-5391825
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53918252017-04-21 Clinical and biochemical study of d-serine metabolism among schizophrenia patients El-Tallawy, Hamdy N Saleem, Tahia H El-Ebidi, Abdallah MAA Hassan, Mohammed H Gabra, Romany H Farghaly, Wafaa MA Abo El-Maali, Nagwa Sherkawy, Hoda S Neuropsychiatr Dis Treat Original Research BACKGROUND: Schizophrenia is a typical N-methyl-d-aspartate receptor (NMDA-R) hypofunction disorder. Decreased d-serine (d-Ser) levels in the periphery occur in schizophrenia and may reflect decreased availability of d-Ser to activate NMDA-R in the brain. OBJECTIVE: The objective of this study was to investigate the role of d-Ser metabolism in the pathogenesis of schizophrenia via biochemical assays and correlates, the serum level of d-Ser, d-serine racemase (SR) (responsible for its formation from l-serine [l-Ser]) and d-amino acid oxidase (DAAO) (responsible for its catabolism), among different clinical types of schizophrenia patients. PATIENTS AND METHODS: This cross-sectional case–control study was carried out on 100 patients and 50 controls. They were recruited from the outpatients’ psychiatric unit of the Neuropsychiatric Department of Assiut University Hospital, Upper Egypt. The type of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), while the severity of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Serum d-Ser levels were estimated using high-performance liquid chromatography (HPLC), while serum SR and DAAO were measured using commercially available enzyme-linked immunosorbent assay kits. RESULTS: There were significantly lower mean serum levels of d-Ser and SR and significantly higher mean serum levels of DAAO (P-value <0.01 for each) among schizophrenia patients when compared with the control group. Paranoid schizophrenia had the highest frequency, with a significantly lower serum levels of d-Ser and SR in the residual type and significantly higher serum levels of DAAO in undifferentiated and catatonic types. Combined receiver-operating characteristic curve for serum d-Ser, SR and DAAO indicated that the best serum level cutoff points at which schizophrenia manifestations started to appear were ≤ 61.4 mg/L for d-Ser, ≤ 15.5 pg/mL for SR and >35.6 pg/mL for DAAO. CONCLUSION: The present study confirms that disturbed d-Ser metabolism could be implicated in the pathogenesis of schizophrenia. Dove Medical Press 2017-04-10 /pmc/articles/PMC5391825/ /pubmed/28435276 http://dx.doi.org/10.2147/NDT.S126979 Text en © 2017 El-Tallawy et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
El-Tallawy, Hamdy N
Saleem, Tahia H
El-Ebidi, Abdallah MAA
Hassan, Mohammed H
Gabra, Romany H
Farghaly, Wafaa MA
Abo El-Maali, Nagwa
Sherkawy, Hoda S
Clinical and biochemical study of d-serine metabolism among schizophrenia patients
title Clinical and biochemical study of d-serine metabolism among schizophrenia patients
title_full Clinical and biochemical study of d-serine metabolism among schizophrenia patients
title_fullStr Clinical and biochemical study of d-serine metabolism among schizophrenia patients
title_full_unstemmed Clinical and biochemical study of d-serine metabolism among schizophrenia patients
title_short Clinical and biochemical study of d-serine metabolism among schizophrenia patients
title_sort clinical and biochemical study of d-serine metabolism among schizophrenia patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391825/
https://www.ncbi.nlm.nih.gov/pubmed/28435276
http://dx.doi.org/10.2147/NDT.S126979
work_keys_str_mv AT eltallawyhamdyn clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT saleemtahiah clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT elebidiabdallahmaa clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT hassanmohammedh clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT gabraromanyh clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT farghalywafaama clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT aboelmaalinagwa clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients
AT sherkawyhodas clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients